

:

<b>Taipei International Breast Cancer Symposium 2022</b> 7F, Taipei Nangang Exhibition Center, Hall 2 <span style="float: right;">Sat., October 1, 2022</span>		
Time	Topic	Speaker
08:20-08:25	Opening Remark	Shou-Tung Chen
08:25-08:30		
08:30-09:00	Should adjuvant chemotherapy be offered to all premenopausal patients with node-positive ER+, HER2- early breast cancer?	Eric P. Winer
09:00-09:30	New horizon of TNBC: clinical outcomes and perspective of A Novel Trop-2 Antibody-Drug conjugate	Hope S. Rugo
09:30-10:00	To whom should adjuvant PARP inhibitors be offered?	Charles E. Geyer
10:00-10:30	Coffee Break	
10:30-11:00	Update 2022 CDK4/6i in HR+ HER2- treatment	Dejan Juric
11:00-11:30	Treatment options of CDK4&6i, S-1, and PARP-i on HR+ early breast cancer: Japan experience	Hiroko Masuda
<b>Educational Section (1) Management of special subtype</b>		
11:30-11:50	Mucinous carcinoma	Yoon-Sim Yap
11:50-12:20	Metaplastic carcinoma of breast: biology, challenges, and strategic direction	Ching-Hung Lin
<b>Satellite Symposium (1)</b>		
12:20-13:00	Luncheon Symposium Thinking outside of the box? What are the possible options for metastatic breast cancer	Wei-Wu Chen
13:00-13:30	Break	
13:30-14:00	Maximizing clinical benefit of atezolizumab in triple negative breast cancer	Chun-Yu Liu
14:00-14:30	The Benefit of Extended Adjuvant Therapy in HER2+ eBC Patients with High Recurrence Risk	Diana Lüftner
14:30-15:00	Genetic testing for hereditary breast cancer - what we've learned today and what to do tomorrow	Wen-Ling Kuo
15:00-15:30	Coffee Break	
15:30-16:00	Raising the bar for patients with HR+/HER2- Early Breast Cancer	Nadia Harbeck
16:00-16:30	Unsolve questions in CDK4/6i mBC setting	Fatima Cardoso
16:30-17:00	HER2 dual blockade treatment benefit on eBC patient survival and Singapore experience with FlexCare	Soo-Chin Lee
17:00-17:30	Past, present and future of HER2+ breast cancer treatment	Paul Cornes

<b>Taipei International Breast Cancer Symposium 2022</b> 7F, Taipei Nangang Exhibition Center, Hall 2 Sun., October 2, 2022		
Time	Topic	Speaker
08:20-08:50	Local-regional management after neoadjuvant therapy	Laura Dominici
08:50-09:20	Local therapy for the primary site in De Novo Stage IV breast cancer	Seema A. Khan
09:20-09:50	Recent progress of antibody-drug conjugate in breast cancer treatment	Shanu Modi
09:50-10:20	Recent advances in Her2 directed therapy in Her2+ ABC	Soo-Chin Lee
10:20-10:40	Coffee Break	
10:40-11:10	Experience sharing: how do we initiate and conduct large scale IIT	Jee Hyun Kim
<b>Satellite Symposium (2)</b>		
11:10-11:40	Identify unmet needs for improving care for patients with chemotherapy-induced neutropenia	Chi-Cheng Huang
11:40-12:10	New Strategic Approach of Neoadjuvant in Early Breast Cancer	Chin-Sheng Hung
12:10-12:50	Luncheon Symposium Recent Roles of Vacuum assisted breast biopsy in Korea	Sang-Won Kim
12:50-13:10	Break	
<b>Educational Section (2) Management of specific metastatic site</b>		
13:10-13:40	Bone-targeted agents for the management of breast cancer patients with bone metastases	Dwan-Ying Chang
13:40-14:00	Pseudocirrhosis: a unique presentation of liver metastasis in advanced breast cancer	Wei-Li Ma
<b>Educational Section (3) Neoadjuvant treatment</b>		
14:00-14:30	Neoadjuvant chemotherapy backbone, which is the optimal option?	Sibylle Loibl
14:30-14:50	Coffee Break	
14:50-15:20	The considerations about adjuvant treatment choices after neoadjuvant therapy	Giampaolo Bianchini
15:20-15:50	Avoiding breast and axillary surgery after neoadjuvant therapy	Joerg Heil
15:50-16:20	Adjuvant radiotherapy after neoadjuvant treatment	Boon H. Chua
16:20-16:40	Panel Discussion	ALL
16:40-17:00	Award Ceremony & Closing	Shou-Tung Chen